- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04746989
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
July 17, 2023 updated by: Rishi J. Desai, Brigham and Women's Hospital
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Probenecid vs Allopurinol
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital.
DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program.
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.
Study Type
Observational
Enrollment (Actual)
294878
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
This study will involve a new user, parallel group, cohort study design comparing probenecid to allopurinol.
The patients will be required to have continuous enrollment during the baseline period of 365 days before initiation of probenecid or allopurinol (cohort entry date).
Follow-up for the outcome (incident dementia), begins the day after drug initiation for analyses 1, 3, and 4 and 180 days after drug initiation for analysis 2.
Description
Please see https://docs.google.com/spreadsheets/d/1N3IVoirGdWS7OiKiOWWgPHhgsSxX7SWDIhpeeZ-Ft7c/edit?usp=sharing or Appendix A for full code and algorithm definitions.
Medicare timeframe: 2007 to 2017 (end of data availability).
Inclusion Criteria:
- 1. No prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date
- 2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
Exclusion Criteria:
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. No prior history of gout recorded in the 365 days prior to cohort entry date
- 3. Prior history of nursing home admission in the 365 days prior to the cohort entry date
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Probenecid
Exposure group
|
Probenecid claim is used as the exposure group.
|
Allopurinol
Reference group
|
Allopurinol claim is used as the reference group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to dementia onset
Time Frame: Through study completion (a median of 243 days)]
|
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere.
Please refer to uploaded protocol for full definition due to size limitations.
|
Through study completion (a median of 243 days)]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Alzheimer's disease onset
Time Frame: Through study completion (a median of 243 days)]
|
Time to Alzheimer's disease onset.
Please refer to uploaded protocol for full definition due to size limitations.
|
Through study completion (a median of 243 days)]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Madhav Thambisetty, MD, PhD, National Institute on Aging (NIA)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 5, 2021
First Posted (Actual)
February 10, 2021
Study Record Updates
Last Update Posted (Actual)
July 18, 2023
Last Update Submitted That Met QC Criteria
July 17, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019A010961-5
- 75N95019C00057 (Other Grant/Funding Number: National Institute on Aging)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Probenecid
-
University of MiamiUnited States Department of DefenseRecruitingInfertility, MaleUnited States
-
University of Maryland, BaltimoreNational Institutes of Health (NIH); National Institute of General Medical...Completed
-
VA Office of Research and DevelopmentRecruiting
-
Iterum Therapeutics, International LimitedAvailableAcute Pyelonephritis | Complicated Urinary Tract Infection
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
TrippBio, Inc.Completed
-
Atea Pharmaceuticals, Inc.RecruitingRenal Impairment | Healthy VolunteerCanada
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
TrippBio, Inc.Not yet recruitingRelative Bioavailability
-
Kelowna General HospitalCapital Health, Canada; Canadian Society of Hospital Pharmacists; Interior Health...Completed